跳到正文
原文
MedPage Today·· 7 天前AI 评分45

他汀类药物在代偿性肝硬化中的另一项有希望的研究

Another Promising Study on Statins in Compensated Cirrhosis

AI 导读

一项大型观察性研究发现,他汀类药物使用者的肝硬化失代偿风险和总体死亡率低于非使用者。研究显示,使用他汀类药物可降低肝硬化失代偿事件的发生率,包括腹水、肝性脑病、食管静脉曲张出血等。

正文

— There are no approved treatments to prevent hepatic decompensation

November 12, 2026 • 2 min read

Statin initiation among adults with compensated cirrhosis was associated with a lower risk of hepatic decompensation and lower overall mortality, according to a large observational study.

Among over 18,000 patients, the cumulative incidence of hepatic decompensation was 18.2% for those who took statins versus 22.7% for those who didn't take statins (adjusted subhazard ratio [aSHR] 0.86, 95% CI 0.78-0.96, P=0.008), reported Monica Tincopa, MD, of the University of California San Diego, at the American Association for the Study of Liver Diseases annual meeting in Denver.

The cumulative incidence of overall mortality was 14.6% for statin users compared with 21.2% for non-users (aSHR 0.77, 95% CI 0.68-0.87, P<0.001).

Over 5 years, the number needed to treat to prevent one episode of decompensation was 25, a number that dropped to 21 over 8 years.

"Decompensation really is the turning point in cirrhosis," Tincopa said. Without approved treatments to prevent decompensation, "current options are really limited to treating the underlying causes of liver disease."

Statins offer potential anti-inflammatory and antifibrotic benefits in cirrhosis, as well as reductions in hepatic portal vein pressure. However, research on statins and decompensation prevention has delivered "highly conflicting" results, Tincopa noted.

Other observational studies have suggested that statin use is associated with lower risks of decompensation and death, including research in veterans with hepatitis C-related compensated cirrhosis. But randomized trials have shown unfavorable results. Ongoing studies such as the phase III SACRED trial of simvastatin in patients with high-risk compensated cirrhosis could bring greater clarity.

The current study included adults with cirrhosis and no prior hepatic decompensation, as determined by ICD-10 codes. Patients with liver transplant or HIV were excluded. The investigators analyzed electronic health record data from the University of California Health Data Warehouse on patients seen at affiliated health facilities from 2012 to 2026.

Statin users and non-users had to have no statin in the 90 days after a cirrhosis diagnosis. Statin users received a prescription after that 90-day lead-in period and had a 90-day qualifying window in which they had no decompensations or deaths. Follow-up for both groups began at 180 days after a cirrhosis diagnosis.

Median age at cirrhosis diagnosis was 58 years, 44% of patients were women, and 51% were white. Metabolic dysfunction-associated steatotic liver disease (MASLD) was the cause of cirrhosis in 73.7% of statin users and 59% of non-users, and the Model for End-Stage Liver Disease score was at least 10 in 2.9% of statin users and 9.4% of non-users. Coronary artery disease was present in 17.9% of statin patients and 3.5% of those who didn't take statins.

The median duration of statin exposure was about 2.6 years, and 75% of statins taken were lipophilic. Median follow-up time was 7.9 years after cirrhosis diagnosis.

First decompensation events were lower in statin users versus non-users, including ascites (12.7% vs 17.1%, respectively), hepatic encephalopathy (4.8% vs 6.5%), variceal bleeding (1.4% vs 2.1%), hepatorenal syndrome (0.3% vs 0.7%), and spontaneous bacterial peritonitis (0.2% vs 0.6%).

Limitations included potential residual confounding and the use of ICD-10 codes to determine cirrhosis and outcomes. The study also didn't assess statin doses or formulations.

来源:MedPage Today · medpagetoday.com